Moss Genomics (MOSS.CN) Stock Price

Moss Genomics, Inc. generates revenue through personalized health, anti-aging, and wellness offerings guided by genomic, microbiome, and epigenome data. The company sells products like Gut Health Complete, Gut + Mental Health Complete, and Personalized Probiotic Products. Its services include home collection kits for saliva and fecal samples, genomic and gut microbiome sequencing, and health reports with actionable wellness recommendations. The firm targets consumers seeking tailored health solutions, leveraging AI to analyze DNA and gut microbiome data. Moss Genomics Holdings Inc., its wholly owned subsidiary, supports these offerings. The company operates in San Diego, California, and offers a Multi-Omics Database to improve pharma and biotech drug development. This database integrates genomic, microbiome, and epigenome data from its consumer base, providing value to pharmaceutical and biotech partners. Moss Genomics, Inc. focuses on delivering personalized health insights through its consumer genetic testing segment, which complements its broader health and wellness product line. Moss Genomics, Inc. provides home collection kits for sample gathering, followed by sequencing and analysis to produce health reports. These reports guide users toward personalized wellness strategies, driving customer engagement and repeat purchases. The company’s business model combines direct-to-consumer health products with data-driven insights for the pharmaceutical industry, creating dual revenue streams from both individual consumers and corporate clients.